Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Uniphar PLC on Tuesday lifted its annual payout and reported revenue growth for 2022.
Shares in Uniphar climbed 6.0% to 310.00 pence each in London on Tuesday morning. It is a Dublin-based healthcare business focused on pharmaceutical and medical technology manufacturers.
Uniphar’s revenue in 2022 grew 6.6% to €2.07 billion from €1.94 billion in 2021. At constant currency, revenue was 6.3% higher.
Pretax profit, however, dipped 2.0% to €54.7 million from €55.8 million. Administrative expenses rose 8.8% to €183.7 million from €168.9 million.
‘The group performed strongly throughout 2022, making further progress against our financial and strategic objectives,’ Chief Executive Officer Ger Rabbette said.
Its total dividend for 2022 amounted to €0.017 per share, up 4.8% from 2021.
Rabbette added: ‘Uniphar is an ambitious organisation, and we are confident of delivering on expectations throughout 2023 and beyond. We remain firmly on track to achieve our strategic objective of doubling 2018 proforma [earnings before interest, tax, depreciation, and amortisation] within 5 years of IPO.’
By Eric Cunha, Alliance News news editor
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.